Oxiracetam
A piracetam-class nootropic developed in the 1970s for cognitive impairment in dementia and post-stroke recovery. Approved in a few European countries decades ago (notably Italy as 'Neuromet'), never approved by the FDA, and withdrawn from most European markets after the EMA cast doubt on the dementia indication. Sold online as a 'research chemical' or gray-market nootropic in the US — not a recognized dietary supplement ingredient.
Research compound — not an approved drug or dietary supplement
This compound is sold for research and is not FDA-approved for human use or as a dietary supplement. Human evidence is limited; purity and dosing of consumer products are unverified. The data below is an evidence review for education only — talk to a clinician before considering it.
Quick decision guide
May help most
No evidence-based indication for healthy adults. The trial-base population is elderly patients with primary degenerative or multi-infarct dementia, and even there the Cochrane and EMA reviews concluded the evidence is insufficient.
Common dosing range
Dementia trials used 1,200–2,400 mg/day in 2–3 divided doses. 'Nootropic' use online: 600–2,400 mg/day with no rigorous human dosing study supporting healthy-adult use.
When to expect effects
Trials ran 8–12 weeks. Subjective acute alertness reported anecdotally; no well-controlled study in healthy adults confirms it.
Watch out for
Not an FDA-approved drug and not a recognized US dietary supplement ingredient. Product quality from research-chemical vendors is unverified — purity, dose accuracy, and contamination are unknown. Long-term safety in healthy adults is undocumented.
Evidence snapshot
What is it
Oxiracetam is a synthetic nootropic compound in the racetam family, structurally similar to piracetam with an added hydroxyl group. It was developed in the late 1970s and is used as a prescription cognitive-enhancing drug in some European countries, but is not approved as a medication or supplement ingredient in the United States.
Is it worth it for you?
Use this as a quick fit check, not a diagnosis.
Worth considering if…
Probably skip if…
Evidence at a glance
| Goal | Effect | Best fit | Time |
|---|---|---|---|
Cognitive function in dementia (vascular and primary degenerative) Limited Evidence | Small improvements on selected cognitive subscales in elderly dementia; uncertain clinical relevance | Elderly patients with multi-infarct or primary degenerative dementia, in countries where oxiracetam is licensed, prescribed by a clinician | 8–12 weeks in trials |
Post-stroke cognitive recovery Limited Evidence | Modest improvements in cognitive testing in small post-stroke RCTs; not in major guidelines | Post-stroke patients in countries where oxiracetam is licensed, under specialist oversight | 8–12 weeks |
Cognitive enhancement in healthy adults ('nootropic' use) Weak Evidence | No reliable human RCT data in healthy adults | None — no evidence base for healthy adults | Not established in healthy adults |
Cognitive function in dementia (vascular and primary degenerative)
- Effect
- Small improvements on selected cognitive subscales in elderly dementia; uncertain clinical relevance
- Best fit
- Elderly patients with multi-infarct or primary degenerative dementia, in countries where oxiracetam is licensed, prescribed by a clinician
- Time
- 8–12 weeks in trials
Post-stroke cognitive recovery
- Effect
- Modest improvements in cognitive testing in small post-stroke RCTs; not in major guidelines
- Best fit
- Post-stroke patients in countries where oxiracetam is licensed, under specialist oversight
- Time
- 8–12 weeks
Cognitive enhancement in healthy adults ('nootropic' use)
- Effect
- No reliable human RCT data in healthy adults
- Best fit
- None — no evidence base for healthy adults
- Time
- Not established in healthy adults
Evidence for 3 uses
AI-assisted evidence assessment — talk to your doctor before relying on any single supplement.
Cognitive function in dementia (vascular and primary degenerative)
Disease adjunctSmall to mid-sized double-blind RCTs in elderly patients with multi-infarct or primary degenerative dementia in the 1980s-90s (Bottini 1992, n=272; Itil 1986; Gallai 1991) reported modest improvements on specific cognitive subscales (attention, short-term memory) at 1,200–1,600 mg/day over 8–12 weeks. Clinical global impression scores moved less convincingly. The closely related Cochrane review of piracetam concluded the evidence does not support racetam use in dementia; oxiracetam-specific evidence faces the same limitations: small trials, dated methods, manufacturer-funded, and the European drug regulator subsequently restricted dementia marketing.
Bottom line: Limited, dated evidence in dementia. Approved dementia therapies (cholinesterase inhibitors, memantine, anti-amyloid agents) have stronger evidence; oxiracetam is not first-line.
Evidence is mixed
Small old RCTs report modest cognitive subscale improvement; Cochrane reviews of the racetam class and EMA regulatory action concluded the evidence is insufficient to recommend racetams for dementia. Most modern dementia guidelines do not include oxiracetam.
Post-stroke cognitive recovery
Disease adjunctSmall Italian and Asian RCTs of oxiracetam 1,200–2,400 mg/day for 8–12 weeks after ischemic stroke have reported improvements on neuropsychological test batteries (memory, attention) and on language outcomes in post-stroke aphasia. Trials are small, single-centre, and inconsistently designed. Major stroke-rehabilitation guidelines do not recommend oxiracetam.
Bottom line: Suggestive but small-sample evidence in post-stroke recovery — not part of standard stroke-rehabilitation guidelines.
Cognitive enhancement in healthy adults ('nootropic' use)
Mechanism onlyOnline nootropic culture treats oxiracetam (and the racetam class generally) as a smart-drug for memory, focus, and verbal fluency. There are essentially no high-quality randomized placebo-controlled trials of oxiracetam in healthy adults. Subjective user reports drive most enthusiasm. Mechanism (cholinergic modulation, AMPA-receptor modulation, membrane fluidity) is plausible but does not substitute for clinical-outcome data in the target population.
Bottom line: Pure extrapolation from old, small dementia trials. Healthy-adult use is unsupported by RCT evidence and product quality is unverified.
How it works
How to take it
What to track
Bottom line: There is no validated healthy-adult dose. Trial doses (1,200–1,600 mg/day, divided) are the closest reference, but the trials were in dementia patients, not you.
3 commercial forms
Compare the main delivery options and what they’re best suited for.
Oxiracetam powder (research chemical)
Online gray marketBulk powder sold by online vendors as a 'research chemical' or nootropic. No regulatory oversight in the US; purity and dose accuracy depend entirely on the vendor's QC. Self-dosing requires a milligram scale.
Same molecule as the European clinical-trial drug; purity is the wildcard.
Oxiracetam capsules
Pre-measured dosePre-measured capsules (typically 600 or 750 mg) from the same online category as the powder. Convenience over powder; identical regulatory and QC concerns.
Standard capsule dissolution; identity verification absent.
Neuromet (oxiracetam, Italfarmaco — historical)
Historical RxItalian prescription brand of oxiracetam, used historically for cognitive impairment in dementia. Marketing has been substantially restricted; not available in the US.
Pharmaceutical-grade manufacturing; not US-available.
Safety
Know the common side effects, key cautions, and who should avoid it.
Common side effects
Serious risks
Product quality from research-chemical and nootropic vendors is unverified — purity, dose accuracy, and contamination (heavy metals, undisclosed pharmaceuticals) are documented concerns across this product class.
Theoretical seizure-threshold lowering — racetams modulate excitatory neurotransmission and should be used cautiously in patients with epilepsy or those on seizure-threshold-lowering medications.
Long-term safety in healthy adults is undocumented — the trial database is short-term (8–12 weeks) and in elderly dementia patients.
Who should avoid it
- Pregnant or breastfeeding women — no safety data.
- Children and adolescents — no efficacy or safety data outside clinical-trial contexts.
- People with severe renal impairment — oxiracetam is renally cleared; accumulation expected. Dose adjustment data are not well-characterized.
- People with active epilepsy or on antipsychotics, antidepressants, or stimulants — discuss with a prescriber before considering racetam-class agents.
- Anyone unable to confirm the source, purity, and dose of the product — this is the modal safety risk for online-sold oxiracetam.
Pregnancy & breastfeeding
Contraindicated in pregnancy and breastfeeding. No adequate human safety data; not an approved drug in the United States; not a recognized dietary supplement ingredient.
Bottom line: Self-administered oxiracetam combines weak evidence with unverified product quality and unknown long-term safety. Not recommended outside clinician-prescribed use in countries where it is licensed.
Interactions
Both classes modulate cholinergic signaling; theoretical additive effect on cognition and on cholinergic side effects (GI, urinary, bradycardia). Limited combination data; discuss with prescribing neurologist.
Stacking multiple racetams is common in nootropic culture but unstudied. Combined cholinergic and AMPA-modulation effects are unpredictable; side-effect burden adds.
Additive activation may worsen anxiety, insomnia, and tachycardia. No controlled combination trials.
Unknown interaction profile; potential to alter cognitive or behavioral effects of prescribed therapy. Don't self-add to a psychiatric regimen.
Some racetams have mild antiplatelet effect in vitro. Clinical relevance with oxiracetam is unclear; flag use to prescriber before any procedure.
Oxiracetam is renally cleared; in renal impairment, accumulation expected. Same caution applies to other renally cleared drugs taken alongside.
Choosing a product
What to look for on the label — and what to be skeptical of.
Look for…
Be skeptical of…
Frequently asked questions
Is oxiracetam legal?⌄
It is a prescription medication in some European countries. In the US, oxiracetam is not approved as a drug or recognized as a dietary supplement ingredient, though it is sold online.
How is oxiracetam different from piracetam?⌄
Oxiracetam is reportedly more stimulating and may have stronger effects on focus and verbal fluency, while piracetam is generally considered more memory-focused. Both share the AMPA modulation mechanism.
Do I need to take choline with oxiracetam?⌄
Many users report that co-supplementing choline (alpha-GPC, CDP-choline) reduces racetam-related headaches and may enhance effects.
Does oxiracetam cause insomnia?⌄
It can. Because of its mildly stimulating effects, taking it earlier in the day is recommended to avoid sleep disruption.
Is oxiracetam safe long-term?⌄
Long-term safety data are limited outside European clinical use. Periodic breaks and clinician oversight are reasonable for extended use.
References by claim
Cognitive function in dementia (vascular and primary degenerative)
Itil et al., 1986 — Drug Development Research (1986) link
Bottini et al., 1992 — Acta Neurologica Scandinavica (1992) link
Gallai et al., 1991 — Acta Neurologica Scandinavica (1991) link
Flicker & Grimley Evans, 2001 (Cochrane) — Cochrane Database of Systematic Reviews (2001) link
Malykh & Sadaie, 2010 — Drugs (Springer) (2010) link
EMA Article 31 Review, 2011 (piracetam class context) — European Medicines Agency (2011) link
Cognitive enhancement in healthy adults ('nootropic' use)
FDA Orange Book — Oxiracetam — FDA approved drug products database (2024) link
Safety
PubChem — Oxiracetam (CID 4626) — NIH PubChem (2024) link
Track Oxiracetam with Pilora
Set up dose reminders, check interactions, and join the community in the Pilora iPhone app.
Coming to App StoreDisclaimer: This compound is not approved by the FDA for human use and is not a dietary supplement. This page is an educational review of available research — much of it preclinical or early-stage — not a recommendation to use it. Consumer product quality is unregulated. Consult a qualified clinician.